This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Bone repair; osteoporosis	Free fatty acid receptor 1 (FFAR1; GPR40)	<p>Studies in mice suggest GPR40 agonists could help prevent bone loss. In mice, <i>Gpr40</i> knockout decreased bone mineral density and bone volume compared with no knockout, and a GPR40 agonist prevented ovariectomy-associated bone loss. Next steps could include evaluating clinical-stage GPR40 agonists in mouse models of osteoporosis and bone loss.</p> <p>Takeda Pharmaceutical Co. Ltd.'s TAK-875, a GPR40 agonist, is in Phase III testing to treat diabetes.</p> <p>Connexios Life Sciences Pvt. Ltd. has two GPR40 agonists, CNX-011-326 and CNX-011-67, in preclinical development for the same indication.</p> <p>SciBX 6(7); doi:10.1038/scibx.2013.165 Published online Feb. 21, 2013</p>	Patent and licensing status unavailable	<p>Wauquier, F. <i>et al. J. Biol. Chem.</i>; published online Jan. 18, 2013; doi:10.1074/jbc.M112.429084</p> <p>Contact: Yohann Wittrant, French National Institute for Agricultural Research (INRA), Clermont-Ferrand, France</p> <p>e-mail: yohann.wittrant@clermont.inra.fr</p>